

Table 1. Description of the European Eye Epidemiology Consortium studies included in the meta-analysis

									Crude prevalence	Crude prevalence
			Data collection period	Total participants	Age Range years	Median age group	Gender, % Male	European ethnicity %	% Early AMD	% Late AMD
Region	Study									
North	United Kingdom	EPIC	2004-2011	5344	45-85+	60-64	43.1	99.7	-	0.5
	Norway	Tromsø	2007-2008	2631	65-85+	65-69	42.5	91	-	3.5
West	France	Alienor-3C	2006-2008	879	70-85+	75-79	37.7	-	16.8	5.6
	Germany	GHS	2007-2012	3839	40-74	50-54	50.2	-	2.3	0.2
	Netherlands	RS-I	1990-1993	6419	55-85+	60-64	40.7	98.9	7.5	1.7
	Netherlands	RS-II	2000-2002	2545	55-85+	55.59	45.4	97.8	6	0.7
	Netherlands	RS-III	2005-2008	3449	45-85+	55-59	43.4	96.4	4.6	0.4
	France	Montrachet	2009-2013	1069	75-85+	80-84	37	100	9.2	2.2
	France	POLA	1995-1997	2196	60-85+	65-69	43.5	-	8.7	1.9
	Portugal	Lousa	2012-2013	3021	55-85+	60-64	43.9	99.3	15.4	1.3
South	Portugal	Mira	2009-2011	2975	55-85+	65-69	43.4	99.7	6.9	0.7
	Thessaloniki	Thessaloniki Eye Study	2000-2005	2107	60-85+	65-69	55.6	97.7	-	2.7
	Italy	PAMDI	2005-2006	853	60-85+	65-69	45.8	100	13.5	2.1
	Multiple	EUREYE	2000-2002	4753	65-85+	65-69	44.8		12.6	3.3

ALIENOR = Antioxydants, Lipids Essentiels, Nutrition et maladies Oculaires Study; EPIC = European Prospective Investigation into Cancer; EUREYE = European Eye Study; GHS= Gutenberg Health Study; POLA= Pathologies Oculaires Liées à l'Age Study; PAMDI = Prevalence of Age-Related Macular Degeneration in Italy; RS= Rotterdam Study

Table 2. Prevalences of Early and Late AMD

Age category	Early AMD		Late AMD	
	Prevalence (%)	95% CI	Prevalence (%)	95% CI
40-44	0.2	no meta-analysis		
45-49	0.9	-0.3- 2.1		
50-54	1.2	-0.7 - 3.2		
55-59	3.5	2.1 - 5.0		
60-64	6.2	4.1 - 8.2		
65-69	7.9	6.0 - 10.0	0.5	0.3 - 0.7
70-74	10.5	8.6 - 12.4	1.1	0.7 - 1.5
75-79	13.4	10.4 - 16.5	2.4	1.7 - 3.1
80-84	15.8	12.9 - 18.8	5.5	3.7 - 7.3
85+	17.6	13.6 - 21.5	9.8	6.3 - 13.3

Figure 1




Figure 1 Composition of population based cohorts subdivided in Early, Late, or no AMD (AMD stage 0 or 1). The name of the study, time of conduction and the abbreviation of the country where the study was performed are depicted. EUREYE represents the European Eye Study and was conducted in 7 European countries. Studies are ranked according to their sample size.

Figure 2




Figure 2 a and b Prevalence of Early (A) and Late (B) AMD per study

The legend shows the study corresponding with the symbol used in the graph including the country and the midpoint year of the recruiting period. The studies Tromsø from Norway, Thessaloniki Eye Study from Greece and EPIC from the UK did not have results for Early AMD.

Abbreviations: AMD = Age-related Macular Degeneration, D = Germany, FR = France, NL = Netherlands, NO = Norway, PT = Portugal, UK = United Kingdom

Figure 3




Figure 3 a, b, c and d Meta-analysis of Early (A) and Late (B) AMD in Europe per age category for the participating studies. Meta-analysis of the prevalence of Early (A) and Late (B) AMD before and after 2006.

Figure 4




Figure 4 a and b Meta-analysis of Early (A) and Late (B) AMD in Europe by ten year birth cohorts.

Figure 5




Figure 5 a and b Meta-analysis of the prevalence of Early (A) and Late (B) AMD for men and women

Figure 6




Figure 6 a, b, c and d Meta-analysis of the prevalence of Early (A) and Late (B) AMD , and of GA (C) and CNV (D) per geographical area.

Figure 7




Figure 7 a and b (A) Proportion of visually impaired eyes within each subgroup of Late AMD. The proportion of visually impaired eyes remained the same for GA (47.6%, p-value= 0.4), but dropped to 66.2% (p-value= 0.026) for CNV after 2006. (B) Proportion of persons with Late AMD with bilateral visual impairment before and after 2006, p-value=0.016.

Figure 8




Figure 8 Predicted number of persons with AMD in years 2013-2040 as a function of two prevalence scenarios.

Figure 9




Figure 9 a, b, c and d Distribution of AMD in people aged 85 years and older from RS1,2,3, Alienor-3C, POLA and Montrachet-3C.